MediciNova, Inc. (MNOV)Healthcare | Biotechnology | La Jolla, United States | NasdaqGM
1.44 USD
+0.02
(1.056%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.44 |
Hot Take ↕ | Aug. 22, 2026, 5:17 a.m. EDT
MediciNova presents a stark dichotomy between aggressive analyst optimism and deteriorating business reality. While analysts project a mean target of $9.00, implying a massive multiple expansion, the company's fundamentals tell a different story. The stock is trading at a forward P/E of -3.09 due to negative earnings, with operating margins crushed at -5.5% and free cash flow burning at nearly -$5.7 million annually. The balance sheet, while currently liquid, relies entirely on cash reserves as there is no debt service pressure yet, but the path to profitability remains obscured. The price history confirms a structural decline, dropping nearly 80% over the last nine years. Although the most recent annual report shows a slight uptick (+7.38%), this follows six years of significant contraction, including a brutal -48% drop in 2024. This recent recovery is insufficient to overcome the multi-year trend of value destruction. The stock is effectively a speculative vehicle betting on a future cure or partnership, priced as if the outcome is certain, despite the high risk of total capital loss given the cash burn rate. Short-term, the stock is technically weak, trading below its 200-day moving average with low volume and no institutional support visible in the options chain. There is no dividend to provide a floor. The disconnect between the 'strong buy' analyst consensus and the hard data suggests the market is pricing in a binary event that may never materialize. For now, the risk-reward profile is skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.030944 |
| MSTL | 0.033759 |
| AutoARIMA | 0.033938 |
| AutoETS | 0.034178 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 0.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.881 |
| Excess Kurtosis | -0.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.314 |
| Revenue per Share | 0.019 |
| Market Cap | 70,632,488 |
| Forward P/E | -3.19 |
| Beta | 0.62 |
| Website | https://medicinova.com |
As of Aug. 22, 2026, 5:17 a.m. EDT: Options activity is extremely sparse with negligible open interest across all expirations. The few contracts present are deep out-of-the-money calls and puts, indicating no meaningful speculative positioning or hedging strategy by market participants. Implied volatility is low, suggesting a lack of anticipated near-term catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.083969474 |
| Address1 | 4,275 Executive Square |
| Address2 | Suite 300 |
| All Time High | 16.12 |
| All Time Low | 1.12 |
| Ask | 1.71 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 53,900 |
| Average Daily Volume3 Month | 50,114 |
| Average Volume | 50,114 |
| Average Volume10Days | 53,900 |
| Beta | 0.62 |
| Bid | 0.9504 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.757 |
| City | La Jolla |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.435 |
| Current Ratio | 8.754 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.4488 |
| Day Low | 1.42 |
| Debt To Equity | 0.314 |
| Display Name | MediciNova |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -11,831,257 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.832 |
| Enterprise To Revenue | 49.25 |
| Enterprise Value | 45,333,604 |
| Eps Current Year | -0.28 |
| Eps Forward | -0.45 |
| Eps Trailing Twelve Months | -0.21 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 404 0048 |
| Fifty Day Average | 1.36 |
| Fifty Day Average Change | 0.07499993 |
| Fifty Day Average Change Percent | 0.055147007 |
| Fifty Two Week Change Percent | 8.396948 |
| Fifty Two Week High | 1.96 |
| Fifty Two Week High Change | -0.5250001 |
| Fifty Two Week High Change Percent | -0.2678572 |
| Fifty Two Week Low | 1.17 |
| Fifty Two Week Low Change | 0.265 |
| Fifty Two Week Low Change Percent | 0.22649573 |
| Fifty Two Week Range | 1.17 - 1.96 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,165,588,200,000 |
| Float Shares | 42,255,947 |
| Forward Eps | -0.45 |
| Forward P E | -3.1888888 |
| Free Cashflow | -5,738,905 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 6 |
| Fullday Change | 0.015 |
| Fullday Change Percent | 1.05634 |
| Fullday Price | 1.435 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.37745997 |
| Gross Profits | 347,443 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02875 |
| Held Percent Institutions | 0.10578 |
| Implied Shares Outstanding | 49,221,246 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. |
| Long Name | MediciNova, Inc. |
| Market | us_market |
| Market Cap | 70,632,488 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9262264 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,753,049 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 70,140,275 |
| Number Of Analyst Opinions | 3 |
| Open | 1.42 |
| Operating Cashflow | -9,110,256 |
| Operating Margins | -5.54313 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 373 1500 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.435 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 1.42 |
| Price Eps Current Year | -5.125 |
| Price Hint | 4 |
| Price To Book | 1.8956405 |
| Price To Sales Trailing12 Months | 76.73432 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.583 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.015 |
| Regular Market Change Percent | 1.05634 |
| Regular Market Day High | 1.4488 |
| Regular Market Day Low | 1.42 |
| Regular Market Day Range | 1.42 - 1.4488 |
| Regular Market Open | 1.42 |
| Regular Market Previous Close | 1.42 |
| Regular Market Price | 1.435 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 16,888 |
| Return On Assets | -0.16412 |
| Return On Equity | -0.25564 |
| Revenue Growth | 2.406 |
| Revenue Per Share | 0.019 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 49,221,246 |
| Shares Percent Shares Out | 0.0067000003 |
| Shares Short | 331,436 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 310,377 |
| Short Name | MediciNova, Inc. |
| Short Percent Of Float | 0.0069 |
| Short Ratio | 9.28 |
| Source Interval | 15 |
| State | CA |
| Symbol | MNOV |
| Target High Price | 11.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 10.0 |
| Total Cash | 25,415,920 |
| Total Cash Per Share | 0.516 |
| Total Debt | 117,038 |
| Total Revenue | 920,481 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.42875 |
| Two Hundred Day Average Change | 0.0062499046 |
| Two Hundred Day Average Change Percent | 0.0043743863 |
| Type Disp | Equity |
| Volume | 16,888 |
| Website | https://medicinova.com |
| Zip | 92,037 |